Effects of the Antidiabetic Drugs on the Age-Related Atrophy and Sarcopenia Associated with Diabetes Type II
Effects of the Antidiabetic Drugs on the Age-Related Atrophy and Sarcopenia Associated with Diabetes Type II
复制标题
DOI：
10.2174/1573399810666140918121022
复制
发表时间：
2014-01-01
影响因子：
3.3
通讯作者：
Tricarico, Domenico
中科院分区：
文献类型：
--
作者：
Cetrone, Michela;Mele, Antonietta;Tricarico, Domenico
骨骼肌萎缩和肌肉减少是老年糖尿病患者治疗中的不良预后因素。胰岛素治疗在年轻患者中刺激蛋白质增加，但在老年患者中没有，并且不能防止萎缩。胰岛素增敏剂格列酮是有前途的抗萎缩药物，但不利的获益/风险概况限制了其使用。二甲双胍是一种AMPK激动剂，在成人肌肉中增强胰岛素作用，但在老年个体中不增强。AMPK激动剂具有诱导萎缩的潜力。KATP通道阻滞剂如磺脲类和格列奈类可诱导萎缩。格列本脲确实在大鼠和人体中诱导萎缩。在格列奈类药物中，瑞格列奈是动物“体外”最有效的萎缩剂。GLP-1和肠促胰岛素在骨骼肌中显示出有益作用，但其对人类和动物中年龄依赖性肌肉萎缩的作用尚不清楚。新型钠葡萄糖协同转运蛋白抑制剂可能尚未被认为具有药物诱导的萎缩/抗萎缩作用。本文就抗糖尿病药物对增龄性肌萎缩的影响作一综述。
The skeletal muscle atrophy and sarcopenia are negative prognostic factors in the treatment of the diabetic aged-population. Insulin therapy stimulated protein anabolism in younger but not older patients and failed to prevent atrophy. The insulin-sensitizer glitazones are promising agents against atrophy but the un-favorable benefit/risk profile limits their use. Metformin is an AMPK agonist potentiating insulin actions in the adult human muscle, but not in the aged individuals. The AMPK agonists have the potential to induce atrophy. The KATP channel blockers such as the sulfonylureas and glinide may induce atrophy. Glibenclamide indeed induces atrophy in rat and in human. Within the glinides, repaglinide is the most potent atrophic agent "in vitro" in animals. The GLP-1 and incretins showed beneficial effects in skeletal muscle but their effects on the age-dependent muscle atrophy in human and animals are not known. The novel sodium glucose co-transporter inhibitors may not have been recognized as drug-induced atrophic/anti-atrophic effects. Here we reviewed the effects of the anti-diabetic drugs on the age-related muscle atrophy.